Cargando…

Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients

BACKGROUND: The aim of this study was to explore the utility of circulating free DNA (cfDNA) in the evaluation of clinical tumor burden and survival in Chinese patients with metastatic colorectal cancer (mCRC) and to preliminarily summarize some metastatic characteristics associated with mutational...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Xiaojing, Yu, Yiyi, Shen, Minna, Liu, Mengling, Wu, Shengchao, Liang, Li, Huang, Fei, Zhang, Chenlu, Guo, Wei, Liu, Tianshu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566057/ https://www.ncbi.nlm.nih.gov/pubmed/33066758 http://dx.doi.org/10.1186/s12885-020-07516-7

Ejemplares similares

Asparaginyl endopeptidase contributes to cetuximab resistance via MEK/ERK signaling in RAS wide-type metastatic colorectal cancer
por: Xu, Xiaojing, et al.
Publicado: (2023)

Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review
por: Xu, Xiaojing, et al.
Publicado: (2022)

Cross‐platform comparison of next‐generation sequencing and matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients
por: Xu, Xiaojing, et al.
Publicado: (2021)

Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer
por: Varkaris, Andreas, et al.
Publicado: (2019)

Prognostic Value of Immunoscore and PD-L1 Expression in Metastatic Colorectal Cancer Patients with Different RAS Status after Palliative Operation
por: Liu, Ruiqi, et al.
Publicado: (2018)

Familial juvenile polyposis syndrome with a de novo germline missense variant in BMPR1A gene: a case report
por: Liu, Qing, et al.
Publicado: (2020)

Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer
por: Spindler, Karen Lise Garm, et al.
Publicado: (2015)

Predicting disease-free survival in colorectal cancer by circulating tumor DNA methylation markers
por: Yang, Xin, et al.
Publicado: (2022)

Chromothripsis and progression-free survival in metastatic colorectal cancer
por: Skuja, Elina, et al.
Publicado: (2017)

FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc
por: Yu, Yiyi, et al.
Publicado: (2016)

Identification of key genes involved in tumor immune cell infiltration and cetuximab resistance in colorectal cancer
por: Liang, Li, et al.
Publicado: (2021)

Perioperative Circulating Tumor DNA in Colorectal Liver Metastases: Concordance with Metastatic Tissue and Predictive Value for Tumor Burden and Prognosis
por: He, Yiping, et al.
Publicado: (2020)

Response to Pyrotinib in a Patient with Metastatic Bladder Urothelial Carcinoma Harboring HER2 V842I Mutation: A Case Report
por: Li, Suyao, et al.
Publicado: (2022)

Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer
por: Boutin, Mélina, et al.
Publicado: (2023)

Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA
por: Berger, Andreas W., et al.
Publicado: (2017)

Role of circulating free DNA in colorectal cancer
por: Matikas, Alexios, et al.
Publicado: (2016)

Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival
por: Sayagués, José María, et al.
Publicado: (2023)

Circulating Cell Free DNA Integrity Index as a Biomarker for Response to Chemotherapy in Patients with Metastatic Colorectal Carcinoma
por: Eskander, Nancy Samir, et al.
Publicado: (2022)

Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
por: Patelli, Giorgio, et al.
Publicado: (2023)

Heparanase modulates the prognosis and development of BRAF V600E-mutant colorectal cancer by regulating AKT/p27Kip1/Cyclin E2 pathway
por: Liu, Mengling, et al.
Publicado: (2022)

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
por: Cicero, Giuseppe, et al.
Publicado: (2018)

High mutation burden of circulating cell‐free DNA in early‐stage breast cancer patients is associated with a poor relapse‐free survival
por: Kujala, Jouni, et al.
Publicado: (2020)

Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study
por: Salvianti, Francesca, et al.
Publicado: (2021)

Hereditary Nonpolyposis Colorectal Cancer and Cancer Syndromes: Recent Basic and Clinical Discoveries
por: Chen, Erbao, et al.
Publicado: (2018)

Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden
por: Zhu, Guanhua, et al.
Publicado: (2021)

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
por: McEvoy, Ashleigh C., et al.
Publicado: (2018)

Metabolic Parameters as Predictors for Progression Free and Overall Survival of Patients with Metastatic Colorectal Cancer
por: Nemeth, Zsuzsanna, et al.
Publicado: (2020)

Molecular Alterations in Circulating Cell-Free DNA in Patients with Colorectal Adenoma or Carcinoma
por: Hu, Ying, et al.
Publicado: (2020)

Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment
por: Pastor, Brice, et al.
Publicado: (2021)

Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials
por: Wang, Jingyuan, et al.
Publicado: (2023)

Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial
por: Xu, Jianming, et al.
Publicado: (2020)

Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients
por: Muendlein, Axel, et al.
Publicado: (2022)

Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response
por: Jia, Ning, et al.
Publicado: (2019)

Circulating tumor DNA applications in monitoring the treatment of metastatic colorectal cancer patients
por: Kazemifard, Nesa, et al.
Publicado: (2019)

Circulating tumor DNA as a therapy response marker in metastatic colorectal cancer
por: Ma, Xiaoju Max, et al.
Publicado: (2022)

Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer
por: Lee, Dae-Won, et al.
Publicado: (2023)

Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review
por: Vymetalkova, Veronika, et al.
Publicado: (2018)

Clinical utility of circulating cell-free DNA in advanced colorectal cancer
por: Pereira, Allan A. Lima, et al.
Publicado: (2017)

Different primers for diagnosing circulating cell-free DNA of colorectal cancer
por: Shi, Hao, et al.
Publicado: (2020)

TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer
por: Hsu, Hung-Chih, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4101evvpftlfsrk6c40mopg7fq